Clinical Guides
Hypertrophic Cardiomyopathy
A clinically focused clinical guide to diagnosing hypertrophic cardiomyopathy, assessing obstruction and sudden-death risk, supporting family screening, and planning treatment and exercise in India.
MedNext Academy | 14 min read
Hypertrophic Cardiomyopathy
A clinically focused clinical guide to diagnosing hypertrophic cardiomyopathy, assessing obstruction and sudden-death risk, supporting family screening, and planning treatment and exercise in India.
Summary
Hypertrophic cardiomyopathy (HCM) is a myocardial disease characterized by increased left-ventricular wall thickness that is not explained solely by loading conditions such as hypertension or valvular disease. It is frequently genetic, most often involving sarcomeric proteins, but the clinical phenotype ranges from lifelong absence of symptoms to exertional limitation, atrial fibrillation, heart failure, stroke, ventricular arrhythmia or sudden cardiac death. Hypertrophy may be asymmetric, concentric, apical or focal. Left-ventricular outflow-tract (LVOT) obstruction is dynamic and can appear only with provocation, so a quiet murmur or low resting gradient does not exclude clinically important obstructive disease.
Diagnosis combines a three-generation family history, examination, ECG and transthoracic echocardiography. Cardiac magnetic resonance (CMR), ambulatory rhythm monitoring, exercise testing, genetic counselling and targeted testing answer specific questions. The clinician must also exclude phenocopies and alternative causes, including hypertensive remodelling, athlete's heart, aortic stenosis, cardiac amyloidosis, Fabry disease, glycogen or lysosomal disease and RASopathy. A sarcomere-gene variant without hypertrophy is genotype-positive/phenotype-negative status, not established clinical HCM.
Management is phenotype- and goal-specific: education and safe activity, symptom control, treatment of obstruction, atrial-fibrillation anticoagulation, heart-failure care, sudden-cardiac-death (SCD) assessment, and screening of relatives. Septal myectomy, alcohol septal ablation, cardiac myosin inhibition and ICD implantation require experienced centres and shared decisions. No single wall-thickness value, genotype result or calculator settles every decision. This quarantined draft has been reviewed by the MedNext Clinical Team and cannot replace specialist interpretation or a local device, imaging, genetics, sports or prescribing pathway.
How Common Is It?
HCM is among the more frequently encountered inherited cardiac conditions, but its reported frequency varies according to whether investigators count imaging-defined disease, pathogenic variants, referral-centre diagnoses or community screening. Contemporary guidance discusses an imaging-recognized prevalence around 1 in 500 adults in some populations, with higher estimates when genotype-positive people are included. These figures are not an Indian national prevalence estimate. India lacks a single comprehensive HCM registry with uniform imaging, genetic criteria and representation across states, ages and healthcare systems.
Ascertainment changes the apparent burden. A tertiary cardiomyopathy clinic enriches for symptomatic, obstructive, familial and device-treated disease; a community echocardiography survey may miss focal or mild phenotypes; and genetic screening identifies people whose hypertrophy has not developed. Penetrance is age-dependent, so a normal study in a young relative is not equivalent to a lifetime negative result. Hypertension, chronic kidney disease and athletic remodelling also complicate case definition. Studies using a wall-thickness threshold without excluding loading conditions can overcount HCM.
The outcomes are equally heterogeneous. Many people have normal longevity, while a minority develop SCD risk, progressive symptoms, atrial fibrillation, embolic stroke or systolic dysfunction. Absolute event rates in modern cohorts are lower than older referral series suggested. This is why population fear should not replace individual assessment. In Indian practice, underdiagnosis may occur where echocardiography or family evaluation is inaccessible, and overdiagnosis may occur when any left-ventricular hypertrophy is labelled HCM. High-quality service planning needs transparent denominators, standardized phenotyping and long-term follow-up rather than an unsupported claim that every region carries the same burden.
Risk Factors
HCM itself is usually not caused by lifestyle risk factors. A pathogenic or likely pathogenic variant in a validated sarcomeric gene can establish familial susceptibility, commonly with autosomal-dominant inheritance and variable penetrance. A parent may appear unaffected because expression is mild, age-dependent or incompletely assessed. De novo disease and non-sarcomeric phenocopies also occur. Hypertension, obesity and sleep apnoea can add haemodynamic load and worsen symptoms or hypertrophy, but their presence does not automatically explain marked, asymmetric or familial disease.
Risk of adverse outcomes must be divided by outcome. For SCD, assess previous cardiac arrest or sustained ventricular arrhythmia, suspected arrhythmic syncope, a family history of premature HCM-related sudden death, maximal wall thickness, left-ventricular apical aneurysm, systolic dysfunction, non-sustained ventricular tachycardia on ambulatory monitoring and the extent of late gadolinium enhancement on CMR. Age and the context, frequency, rate and duration of non-sustained VT matter. These markers support shared ICD decisions; they are not interchangeable and should be reassessed every one to two years or after clinical change.
Heart-failure and stroke risks have different drivers. Dynamic LVOT obstruction, mitral systolic anterior motion, diastolic dysfunction, myocardial ischaemia and chronotropic limitation can reduce exercise capacity. Atrial enlargement and atrial fibrillation increase embolic risk. Progressive fibrosis, an apical aneurysm or ejection fraction below the expected preserved range can signal adverse remodelling. Dehydration, vasodilation, fever and abrupt preload reduction may intensify obstruction. Exercise is not a generic risk factor to be prohibited: contemporary data do not support universal restriction, but symptom status, SCD profile, treatment, device and sport determine the individual plan.
Diagnosis
History
Ask about exertional breathlessness, chest discomfort, presyncope or syncope, palpitations, reduced performance, orthopnoea and ankle swelling. Clarify whether syncope occurred during exertion, immediately after it, with dehydration or without warning. Record hypertension severity and duration, kidney disease, valve disease, neuromuscular or metabolic symptoms, carpal-tunnel history, neuropathy, angiokeratomas, learning or syndromic features, and medicines. Build a three-generation pedigree covering HCM, heart failure, unexplained sudden death, drowning, ICDs, transplantation and early stroke.
Examination
Measure pulse and blood pressure and assess congestion, perfusion and rhythm. An ejection systolic murmur may increase with standing or Valsalva and decrease with squatting, but absence of a murmur does not exclude HCM. Look for a bifid pulse, forceful apex, fourth heart sound and mitral regurgitation. Search for phenocopy clues without treating them as diagnostic. Orthostatic observations and a supervised provocative manoeuvre can add context; do not provoke an unstable or recently syncopal patient.
Investigations
Obtain a 12-lead ECG and transthoracic echocardiogram measuring distribution and maximal thickness, cavity size, systolic and diastolic function, left atrium, mitral apparatus and LVOT gradient at rest and with Valsalva. If the resting gradient is below 50 mmHg and symptoms suggest obstruction, exercise echocardiography is preferred to unphysiological provocation when available. CMR clarifies poor echo windows, apical or focal hypertrophy, scar, apical aneurysm and phenocopies. Perform 24- to 48-hour ambulatory ECG at baseline and periodically; extend monitoring when symptoms are intermittent. Exercise testing assesses function, blood pressure and arrhythmia. Genetic testing follows counselling and a convincing phenotype, not an isolated machine label.
Differential Diagnosis
Hypertensive heart disease is the commonest practical alternative. Long-standing severe pressure load usually produces concentric hypertrophy, but overlap is substantial and blood pressure may coexist with sarcomeric HCM. Reassess the history, distribution of thickness, family pattern, ECG, CMR and response to pressure control. Aortic stenosis and subaortic membrane cause pressure loading or obstruction that must be anatomically distinguished. Athlete's heart usually has proportionate cavity enlargement and physiological adaptation; detraining, diastolic indices, CMR and family/genetic information may help when the grey zone persists. Never clear sport from wall thickness alone.
Phenocopies have treatment and family implications. Cardiac amyloidosis can produce increased wall thickness, low-voltage discordance, neuropathy, carpal-tunnel syndrome or characteristic imaging. Fabry disease may present with renal, neurological, skin or ocular features. Danon disease, PRKAG2-related glycogen storage, Pompe disease, mitochondrial disorders and RASopathies enter the differential according to age and extracardiac clues. A phenocopy-oriented genetic panel is useful only with counselling and expert interpretation.
Other cardiomyopathies can remodel with hypertrophy, including dilated or arrhythmogenic disease, myocarditis and left-ventricular noncompaction. An apical tumour or prominent trabeculation may mimic focal hypertrophy. Coronary disease, microvascular ischaemia, asthma, anaemia, obesity, deconditioning and pulmonary disease can explain symptoms in a patient who also has HCM. A dynamic murmur can resemble mitral regurgitation, and chest pain does not prove LVOT obstruction. The final diagnosis should state the phenotype, maximum thickness, obstruction at rest or provocation, suspected aetiology and unresolved alternatives rather than using HCM as an undifferentiated label.
Management
Begin with education, shared decision-making and longitudinal ownership. Explain inheritance, symptom and emergency triggers, hydration during illness, medicine review, exercise principles and why relatives need staged evaluation. Treat hypertension, obesity, sleep apnoea and vascular risk without causing avoidable hypotension or preload loss in obstructive physiology. Mild-to-moderate recreational activity is encouraged for most stable patients; vigorous or competitive sport requires individualized discussion after complete evaluation, not an automatic ban or unrestricted clearance.
For symptomatic obstructive HCM, use a non-vasodilating beta-blocker first when suitable. If ineffective or not tolerated, verapamil or diltiazem may be considered, except in important hypotension, severe resting symptoms or very high gradients. Persistent limiting symptoms after appropriate trials prompt an HCM-centre discussion of an adult cardiac myosin inhibitor, disopyramide with rate-control therapy, or septal reduction. Surgical myectomy is preferred when another surgical cardiac lesion needs correction and is performed by an experienced team. Alcohol septal ablation is an alternative for selected adults when surgery is unsuitable or after a balanced expert choice; anatomy and local outcomes matter.
Manage atrial fibrillation promptly because loss of atrial contribution and fast rate can be poorly tolerated. Anticoagulation is recommended for clinical AF and sufficiently sustained device-detected AF in HCM irrespective of the ordinary CHA2DS2-VASc threshold, with agent choice individualized. Treat ventricular arrhythmia and heart failure according to phenotype; ejection fraction below 50% in HCM signals systolic dysfunction and changes therapy. An ICD prevents sudden arrhythmic death but does not improve obstruction or ordinary symptoms. Secondary-prevention indications are strong; primary prevention requires repeated risk assessment, device-complication counselling and patient preference.
Prescribing Information
Non-vasodilating beta-blockers are titrated to symptom response, heart rate, blood pressure and adverse effects. Record the exact agent and formulation and review fatigue, bronchospasm, bradycardia, conduction disease, erectile effects, pregnancy and masking of hypoglycaemia. Verapamil or diltiazem can improve symptoms when beta-blockers are unsuitable, but avoid casual use in severe obstruction with hypotension or rest symptoms. Combining a beta-blocker with a non-dihydropyridine calcium-channel blocker can cause bradycardia or heart block and lacks routine supporting evidence in HCM. Dihydropyridine vasodilators, nitrates and excessive diuresis may worsen dynamic obstruction in susceptible patients; another compelling indication requires a monitored individualized plan.
Disopyramide requires specialist initiation because of anticholinergic effects, QT prolongation, interactions and proarrhythmia. Cardiac myosin inhibitors require a dedicated programme: confirm obstructive phenotype and eligibility, check interacting drugs and pregnancy potential, obtain serial echocardiographic ejection-fraction monitoring and interrupt treatment according to the licensed protocol. Mavacamten can cause systolic dysfunction and fetal harm. Trial evidence is strongest in selected symptomatic adults with obstructive HCM; it should not be generalized to children, pregnancy, nonobstructive disease or every healthcare setting. Availability and regulatory status must be checked in India at the time of treatment.
For HCM with atrial fibrillation, a direct oral anticoagulant is commonly first-line unless contraindicated; valve disease, kidney function, body weight, interactions, pregnancy, bleeding history and affordability affect choice. Conventional heart-failure drugs are used when systolic dysfunction develops, but specialist review is essential because obstructive and nonobstructive physiology differ. Avoid over-the-counter decongestants, stimulants, unregulated performance products and abrupt medication changes. Every prescription review should ask whether it alters heart rate, preload, afterload, rhythm, renal function or the safety of a planned myosin inhibitor.
When to Refer
Refer a suspected case to cardiology when unexplained hypertrophy, an HCM-pattern ECG, a dynamic systolic murmur, exertional syncope, documented ventricular arrhythmia or a first-degree family history is present. Urgency increases after exertional syncope, sustained ventricular tachycardia, resuscitated arrest, rapid symptom progression, new heart failure, chest pain with instability or a family cluster of premature deaths. Send original echo images and reports, ECGs, ambulatory recordings, exercise data, blood-pressure history, medicines, pedigree and prior genetic reports; a copied phrase such as severe HCM is not an adequate handover.
An experienced HCM centre is particularly valuable when the diagnosis is uncertain, a phenocopy is possible, imaging disagrees, genetic testing is contemplated, SCD risk is borderline, competitive sport or pregnancy is being planned, symptoms persist despite initial medicines, or an ICD, myosin inhibitor or septal reduction procedure is considered. Septal myectomy and alcohol ablation should not be offered by procedural volume alone; discuss operator and centre outcomes, anatomical suitability, pacing risk, residual obstruction and long-term follow-up.
First-degree relatives need a coordinated pathway. If the proband has a pathogenic or likely pathogenic variant, offer counselling and targeted cascade testing. Relatives who carry it receive age-appropriate ECG and imaging surveillance even before hypertrophy develops. When no causative variant is found or testing is not feasible, clinical screening continues because the family phenotype remains informative. Children are generally reassessed more often than stable adults; intervals shorten with symptoms or family severity. In India, the referring clinician should establish which centre can provide CMR, paediatric cardiology, genetics, electrophysiology and surgery, while maintaining a safe local monitoring and emergency plan.
Red Flags
Call emergency services for cardiac arrest, sustained ventricular tachycardia, syncope during exertion with ongoing symptoms, severe chest pain, pulmonary oedema, shock or a new neurological deficit. Stabilize airway, breathing and circulation, record rhythm and obtain urgent cardiology input. Do not send an unstable patient for an outpatient echo. Ventricular arrhythmia may occur without a dramatic murmur, and a patient can have HCM plus acute coronary syndrome, pulmonary embolism, aortic disease or another emergency.
In known HCM, concerning progression includes new or more frequent syncope, rapidly declining exercise tolerance, orthopnoea, resting breathlessness, sustained palpitations, device therapy, new atrial fibrillation, embolic symptoms or an ejection fraction below 50%. Hypotension after dehydration, vasodilator exposure or excessive diuresis may reflect worsened dynamic obstruction. Fever and a red or draining ICD wound raise device-infection concern. Multiple shocks require emergency rhythm and device assessment; a magnet or reprogramming is not an unsupervised home intervention.
SCD-risk red flags are a previous arrest or sustained ventricular arrhythmia, suspected arrhythmic syncope, premature HCM-related sudden death in close relatives, extreme hypertrophy, apical aneurysm, systolic dysfunction, meaningful non-sustained VT and extensive scar. They prompt expert review, not automatic implantation from a checklist. Exercise-associated chest pain, presyncope, unusual breathlessness or palpitations should stop activity pending assessment. Pregnancy with syncope, arrhythmia or heart-failure symptoms needs coordinated obstetric-cardiology care. A genotype-positive relative with no hypertrophy is not disease-free for life and needs follow-up, but an ICD is not implanted merely to permit sport or because the family variant is present.
Indian Clinical Context
Indian patients may move between small clinics, general cardiology services and distant tertiary centres, so diagnostic continuity is a safety intervention. Echo reports should state maximal wall thickness by segment, LVOT gradient at rest and with a physiological manoeuvre, mitral systolic anterior motion, regurgitation, systolic function and relevant alternatives. When CMR, stress echocardiography or prolonged monitoring is unavailable locally, document the unanswered question and arrange the most appropriate referral instead of presenting a limited study as definitive. Teleconsultation can support triage but cannot replace image quality or emergency care.
Genetic testing access and quality vary. Use a laboratory with transparent accreditation, validated HCM and phenocopy genes, modern classification, confirmatory methods and a route for counselling and variant reinterpretation. Large indiscriminate panels increase uncertain findings. A VUS must not be used to declare children affected, release relatives from screening or select an ICD. Discuss costs and insurance or public-scheme eligibility before sampling; do not promise coverage. Families may prefer staged phenotypic screening while funding is resolved.
Advanced treatments are also unevenly distributed. ICD care requires reliable implantation, interrogation, lead and generator follow-up, and emergency response after shocks. Septal myectomy needs a high-experience surgical team; alcohol septal ablation needs suitable coronary anatomy and interventional expertise. A new drug's Indian authorization, supply, monitoring system and price must be checked rather than inferred from a US guideline. Where travel is necessary, give an interim medicines supply, red-flag plan and named local clinician. Encourage culturally and occupationally realistic activity rather than telling every patient to avoid exertion, and coordinate school, work, pregnancy and family screening without stigma or deterministic language.
NMC Competency Mapping
The NMC CBME Curriculum 2024 maps the core pathology of cardiomyopathy to PA26.9: learners should classify cardiomyopathies and describe their aetiology, types, pathophysiology, gross and microscopic pathology, diagnosis and complications. PY5.5 provides ECG physiology and applications, while PY5.6 covers abnormal waveforms, intervals and arrhythmias. These are the direct undergraduate anchors for understanding hypertrophy, diastolic dysfunction, outflow obstruction and rhythm risk. Heart-failure history, examination and management competencies provide vertical clinical integration, but HCM-specific invasive treatment remains specialist practice.
At Know and Know How levels, the learner should distinguish HCM from secondary hypertrophy, explain autosomal-dominant inheritance with variable penetrance, describe asymmetric septal and apical patterns, and connect systolic anterior motion to dynamic obstruction and mitral regurgitation. ECG learning includes left-ventricular hypertrophy patterns, repolarisation change, pathological Q waves and arrhythmias without treating any one sign as diagnostic. Pathology should connect myocyte hypertrophy and disarray with fibrosis while recognizing that biopsy is not routinely required for diagnosis.
At Show How level, a learner can take a three-generation pedigree, examine a systolic murmur with safe physiological manoeuvres, interpret a structured echocardiography report, identify an urgent syncopal presentation and hand over SCD markers. Learners should explain why first-degree relatives need follow-up and why a VUS is not predictive. They should not independently clear competitive sport, initiate disopyramide or a myosin inhibitor, select an ICD or choose septal ablation versus myectomy. Assessment should reward the sequence: confirm phenotype, exclude mimics, characterize obstruction, assess rhythm and SCD risk, then involve the family and specialist team.
Key Exam Pearls for NEET PG
HCM is otherwise unexplained left-ventricular hypertrophy, commonly caused by autosomal-dominant sarcomeric disease with variable penetrance. Asymmetric septal hypertrophy is classic but not universal. Dynamic LVOT obstruction results from septal hypertrophy plus systolic anterior motion of the mitral valve; the murmur usually increases when preload falls, as with standing or Valsalva, and decreases with squatting. A normal or quiet examination does not exclude nonobstructive or provocable disease. Echocardiography is first-line; CMR clarifies morphology, apical disease, scar, aneurysm and mimics.
Symptoms include exertional dyspnoea, chest pain, palpitations, presyncope and syncope. The ECG may show LVH, repolarisation abnormalities, deep narrow Q waves or giant negative T waves in apical HCM, but no pattern is independently diagnostic. Major SCD assessment domains include previous arrest or sustained VT, arrhythmic syncope, family history of premature HCM-related death, maximal wall thickness, apical aneurysm, non-sustained VT, systolic dysfunction and CMR fibrosis. Reassess over time. An ICD is clear secondary prevention after arrest or sustained VT and a shared primary-prevention decision in selected high-risk patients.
Treat symptomatic obstruction first with a non-vasodilating beta-blocker; verapamil or diltiazem is an alternative in suitable patients. Persistent symptoms prompt specialist consideration of disopyramide, a cardiac myosin inhibitor or septal reduction. Avoid dehydration and unexamined preload or afterload reduction. HCM with atrial fibrillation generally warrants anticoagulation irrespective of the usual CHA2DS2-VASc score. Encourage mild-to-moderate recreational exercise; competitive or vigorous sport is individualized. Offer genetic counselling and test relatives only for a causative familial variant, while continuing ECG and imaging surveillance when the phenotype is familial but genetics is negative.
Frequently Asked Questions
Does every person with thickened heart muscle have hypertrophic cardiomyopathy?
No. Hypertension, aortic stenosis, athletic adaptation, amyloidosis, Fabry disease and other metabolic or syndromic conditions can increase wall thickness. Diagnosis requires the distribution and degree of hypertrophy to be interpreted with loading conditions, symptoms, family history, ECG, echocardiography and sometimes CMR or genetics. A borderline measurement should be repeated or reviewed from the original images before a lifelong inherited diagnosis is assigned.
Does hypertrophic cardiomyopathy always require an implantable cardioverter-defibrillator?
No. An ICD is strongly considered after cardiac arrest or sustained ventricular arrhythmia and may be appropriate for selected primary-prevention patients after structured SCD-risk review. It does not treat obstruction or ordinary symptoms and carries infection, lead, inappropriate-shock and replacement risks. The decision uses clinical history, family history, imaging and rhythm findings, age and patient preferences; one wall-thickness measurement or genetic result should not determine it alone.
Can people with hypertrophic cardiomyopathy exercise safely?
Most stable patients should be encouraged to undertake mild-to-moderate recreational activity after clinical assessment. Modern evidence does not support universal prohibition of vigorous activity, but it also does not make every sport safe for every patient. Symptoms, obstruction, arrhythmias, SCD markers, medicines, ICD status and the proposed setting matter. Competitive or high-intensity participation should follow expert shared decision-making, emergency planning and regular reassessment. Stop exercise and seek review after syncope, chest pain or sustained palpitations.
What screening do the children and siblings of a patient with HCM need?
First obtain a three-generation pedigree and genetic counselling for the affected person. If a pathogenic or likely pathogenic familial variant is found, relatives can have targeted testing plus age-appropriate clinical follow-up when positive. If testing is negative, unavailable or uninformative, first-degree relatives still need periodic ECG and echocardiography because penetrance is age-dependent. Children are usually reviewed more frequently than stable adults, and any new symptom or severe family history shortens the interval.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic